Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer.
Standard
Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer. / Müller, Volkmar; Thomssen, Christoph; Schmidt, Marcus; Glados, Manfred; Jackisch, Christian; Heilmann, Volker; Hinke, Axel; Lehnert, Antje; Borowicz, Henryk; Möbus, Volker.
In: BMC CANCER, Vol. 10, 2010, p. 430.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer.
AU - Müller, Volkmar
AU - Thomssen, Christoph
AU - Schmidt, Marcus
AU - Glados, Manfred
AU - Jackisch, Christian
AU - Heilmann, Volker
AU - Hinke, Axel
AU - Lehnert, Antje
AU - Borowicz, Henryk
AU - Möbus, Volker
PY - 2010
Y1 - 2010
N2 - The integration of the non-cross-resistant chemotherapeutic agents capecitabine and vinorelbine into an intensified dose-dense sequential anthracycline- and taxane-containing regimen in high-risk early breast cancer (EBC) could improve efficacy, but this combination was not examined in this context so far.
AB - The integration of the non-cross-resistant chemotherapeutic agents capecitabine and vinorelbine into an intensified dose-dense sequential anthracycline- and taxane-containing regimen in high-risk early breast cancer (EBC) could improve efficacy, but this combination was not examined in this context so far.
U2 - 10.1186/1471-2407-10-430
DO - 10.1186/1471-2407-10-430
M3 - SCORING: Zeitschriftenaufsatz
VL - 10
SP - 430
JO - BMC CANCER
JF - BMC CANCER
SN - 1471-2407
ER -